Search

Your search keyword '"Elamin, Y. Y."' showing total 7 results
Start Over Author "Elamin, Y. Y."
7 results on '"Elamin, Y. Y."'

2. Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions

Author

Madison R. W., Gupta S. V., Elamin Y. Y., Lin D. I., Pal S. K., Necchi A., Miller V. A., Ross J. S., Chung J. H., Alexander B. M., Schrock A. B., Heymach J. V., Reddy P., Ali S. M., Madison, R. W., Gupta, S. V., Elamin, Y. Y., Lin, D. I., Pal, S. K., Necchi, A., Miller, V. A., Ross, J. S., Chung, J. H., Alexander, B. M., Schrock, A. B., Heymach, J. V., Reddy, P., and Ali, S. M.

Subjects
Male, TAK-788, Carcinoma, Transitional Cell, Urologic Neoplasms, Receptor, ErbB-2, EGFR, DNA, Neoplasm, Middle Aged, ERRB2, ErbB Receptors, urothelial cancer, Mutation, Biomarkers, Tumor, exon 20, Humans, Female, poziotinib, Aged
Abstract

Objective: To review the genomic landscape of advanced urothelial carcinoma (UC) to assess the frequencies of EGFR and ERBB2 (HER2) alterations. Materials and Methods: Tumour specimens from 3753 patients with advanced UC were assayed with hybrid capture-based comprehensive genomic profiling of 180–395 genes. Tumour mutational burden (TMB) was assessed on 0.8 or 1.1Mb of DNA, and is reported as mutations per megabase. Results: In 3753 cases of UC, EGFR alterations were detected in 4.1% (154) and were most commonly amplifications (64%; 99/154), while exon 20 insertions (EGFRexon20ins) were the second most common alteration (18%; 27/154). Alterations in ERBB2 were observed in 15% (552/3753) of cases and, similarly, ERBB2 amplification was the most commonly observed alteration (278/552; 50%); ERBB2exon20ins occurred in 3.6% (20/552) of cases. EGFRexon20ins and ERBB2exon20ins occurred in younger patients (median age 62 vs 69years, P = 2.6E-2 and 60 vs 68years, P = 7.8E-4), and these cases had significantly lower TMB (median 3.6 vs 7.2, P = 2.7E-4 and 2.5 vs 10, P = 1.2E-7) and less frequent TP53 alterations (3.7% vs 83%, P = 4.3E-14 and 20% vs 68%, P = 9.8E-4) compared to cases with other EGFR or ERBB2 alterations. Conclusion: EGFR and ERBB2 alterations occur in 4% and 15% of UC, respectively. EGFRexon20ins and ERBB2exon20ins were present in 0.7% and 0.5% of UC overall and collectively define a small, but distinct, subset of UC with infrequent co-occurrence of other drivers and low TMB. Given recent promising clinical studies of inhibitors with activity against exon 20 insertions in non-small cell lung cancer, consideration should be given to developing a trial inclusive of patients with UC harbouring these alterations.

Published
2020

3. LIBRETTO-431: Selpercatinib in treatment (Tx)-naive patients with RET fusion-positive (RET plus ) non-small cell lung cancer (NSCLC)

Author

Loong, H. H. F., Goto, K., Elamin, Y. Y., Solomon, B., Santini, F. C., Soldatenkova, V., Sashegyi, A., Lin, A. Bence, Lin, B. K., Wolf, J., Oxnard, G. R., Zhou, C., Drilon, A., Park, K., Loong, H. H. F., Goto, K., Elamin, Y. Y., Solomon, B., Santini, F. C., Soldatenkova, V., Sashegyi, A., Lin, A. Bence, Lin, B. K., Wolf, J., Oxnard, G. R., Zhou, C., Drilon, A., and Park, K.

Published
2020

5. A rare case of nasopharyngeal carcinoma with widespread CNS metastases

Author

Rafee, S., Elamin, Y. Y., Cronin, K., sinead Brennan, and Osman, N.

Subjects
Adult, Brain Neoplasms, Carcinoma, Humans, Antineoplastic Agents, Nasopharyngeal Neoplasms, Chemoradiotherapy, Spinal Cord Neoplasms
Abstract

Nasopharyngeal cancer is unique among head and neck cancers. Despite definitive treatment, there is a high rate of recurrence, most commonly in the bone, lung or liver. Brain metastases and particularly, leptomeningeal carcinomatosis are extremely rare. We present a case of recurrent nasopharyngeal carcinoma with brain metastases and leptomeningeal carcinomatosis in the absence of local recurrence and systemic metastases.

Catalog

Books, media, physical & digital resources
See catalog results